Ghrelin: The Hunger Hormone

Ghrelin is one of the most distinctive hormones in human physiology: it is the only known circulating hormone that makes us hungry. Where most gut hormones tell the brain to stop eating, ghrelin does the opposite. Understanding it opens a window onto how the body decides when to seek food — and onto a family of drugs designed to switch that signal on when illness has turned it off.

What ghrelin is

Ghrelin is a 28-amino-acid peptide produced mainly by specialized cells in the lining of the stomach. It is the body's own molecule — not a medication — and it circulates in the blood to reach its targets. Its levels follow a clear rhythm: ghrelin rises before meals, peaking when the stomach is empty, and falls after eating. This pattern is why it is often called the "hunger hormone."

To become active, ghrelin must be chemically modified. An enzyme called GOAT (ghrelin O-acyltransferase) attaches an octanoyl group to the peptide, producing acyl-ghrelin, the form that engages its receptor. This unusual fatty-acid modification is essential — without it, ghrelin cannot signal hunger.

How it works

Acyl-ghrelin acts on the growth hormone secretagogue receptor type 1a (GHSR-1a), found in the hypothalamus, pituitary, and elsewhere. Through this receptor ghrelin does two headline things:

• Stimulates appetite. It activates the brain's appetite-regulation circuitry — particularly the NPY/AgRP neurons of the hypothalamic arcuate nucleus — to increase the drive to eat.
• Triggers growth hormone release. Acting on the pituitary, it prompts a pulse of growth hormone, which is why GHSR-1a agonists are grouped as growth hormone secretagogues.

Ghrelin also contributes to gut motility, participating in the fasting "housekeeper" contractions described in the migrating motor complex. In every sense it is a fasting-state signal: it prepares the body to find, take in, and process food. It works in balance against the satiety hormones that dominate after a meal.

Why researchers care

Because ghrelin so reliably drives appetite and growth hormone, scientists have long asked whether a synthetic GHSR-1a agonist could help patients who have lost the will or ability to eat. This has produced an emerging class of investigational and niche-approved drugs that mimic ghrelin:

• Anamorelin is an oral ghrelin-receptor agonist developed for cancer cachexia — the profound wasting seen in advanced cancer. It is not FDA-approved; its trials improved lean body mass and appetite but did not clearly improve physical function, so U.S. regulators declined it. It is approved in Japan for certain cancers. See anamorelin for cancer cachexia.
• Relamorelin is an injectable ghrelin-receptor agonist being studied as a prokinetic for diabetic gastroparesis. It is investigational and not approved.
• Macimorelin is an approved oral ghrelin-receptor agonist, but used as a diagnostic to test growth hormone deficiency rather than to stimulate appetite.

These agents illustrate a recurring theme in peptide medicine: a hormone the body makes for one purpose can be reproduced as a drug when disease disrupts the natural signal.

The bigger picture

Ghrelin rarely acts alone. It is one voice in a conversation that also includes leptin from fat tissue, insulin, and the post-meal satiety hormones such as PYY and GLP-1. The brain integrates all of these to set hunger and fullness moment to moment. That is why simply raising or lowering one signal seldom produces lasting weight change on its own, and why ghrelin-based drugs are aimed at specific clinical problems — wasting, poor appetite, slow stomach emptying — rather than being marketed as consumer supplements.

> This article is educational and not medical advice. Ghrelin is a natural hormone, not a product for sale; its drug analogs are prescription or investigational medicines used under clinical supervision.